Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Femasys ( (FEMY) ) has shared an update.
On August 25, 2025, Femasys Inc. entered into an underwriting agreement with JonesTrading Institutional Services LLC and Laidlaw & Company (UK) Ltd. for a public offering of shares and warrants, expecting to raise $8 million. The proceeds will be used for commercial expansion, product development, and general corporate purposes, with the offering set to close on August 27, 2025.
The most recent analyst rating on (FEMY) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.
Spark’s Take on FEMY Stock
According to Spark, TipRanks’ AI Analyst, FEMY is a Underperform.
Femasys faces significant financial and technical challenges, with persistent losses and bearish market indicators. While recent regulatory approvals are positive, they are overshadowed by financial instability and compliance risks.
To see Spark’s full report on FEMY stock, click here.
More about Femasys
Femasys Inc. operates in the healthcare industry, focusing on the development and commercialization of medical devices and products. The company is dedicated to advancing women’s healthcare through innovative solutions.
Average Trading Volume: 574,886
Technical Sentiment Signal: Sell
Current Market Cap: $12.25M
For a thorough assessment of FEMY stock, go to TipRanks’ Stock Analysis page.